Expert review of anti-infective therapy · 2026
Resistance of uropathogens to fosfomycin: an evaluation of the published evidence.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Katsikas Konstantinos Μ, Poziou Panagiota, Stavroulakis Panagiotis, Paliogianni Paraskevi Maria, Filippou Charalampos, Falagas Matthew E
Аннотация
INTRODUCTION: Fosfomycin has reemerged as a therapeutic option for both uncomplicated and complicated urinary tract infections (UTIs), demonstrating in vitro activity even against isolates with advanced antimicrobial resistance profiles. This review aimed to evaluate its in vitro activity against common urinary pathogens.
AREAS COVERED: Overall, 41 studies comprising 25,689 urinary isolates of Escherichia coli, Klebsiella pneumoniae, and Enterococcus faecalis were included. Among E. coli isolates, resistance was 1.2%-54.1% and 0%-63.2% according to EUCAST and CLSI breakpoints, respectively (with 0.5%-1.5% intermediate according to CLSI). Among K. pneumoniae isolates, resistance was 13.1%-88.2% and 0%-73.6% according to EUCAST and CLSI breakpoints, respectively (with 1.6%-3.2% intermediate according to CLSI). Lastly, among E. faecalis isolates, resistance was 2.6%-66.5% and 2.1%-11.6% according to EUCAST and CLSI breakpoints, respectively.
EXPERT OPINION: Although routine susceptibility testing is methodologically challenging, the available data suggest that fosfomycin demonstrates in vitro activity against a considerable proportion of uropathogens. However, the use of fosfomycin in clinical practice should be guided by in vitro susceptibility testing results, given that the proportion of uropathogens resistant to the antibiotic may vary, especially in hospitalized patients. Emerging data suggest a role of fosfomycin against multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-negative uropathogens, especially in combination therapy.
AREAS COVERED: Overall, 41 studies comprising 25,689 urinary isolates of Escherichia coli, Klebsiella pneumoniae, and Enterococcus faecalis were included. Among E. coli isolates, resistance was 1.2%-54.1% and 0%-63.2% according to EUCAST and CLSI breakpoints, respectively (with 0.5%-1.5% intermediate according to CLSI). Among K. pneumoniae isolates, resistance was 13.1%-88.2% and 0%-73.6% according to EUCAST and CLSI breakpoints, respectively (with 1.6%-3.2% intermediate according to CLSI). Lastly, among E. faecalis isolates, resistance was 2.6%-66.5% and 2.1%-11.6% according to EUCAST and CLSI breakpoints, respectively.
EXPERT OPINION: Although routine susceptibility testing is methodologically challenging, the available data suggest that fosfomycin demonstrates in vitro activity against a considerable proportion of uropathogens. However, the use of fosfomycin in clinical practice should be guided by in vitro susceptibility testing results, given that the proportion of uropathogens resistant to the antibiotic may vary, especially in hospitalized patients. Emerging data suggest a role of fosfomycin against multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-negative uropathogens, especially in combination therapy.